Radius Health Inc., of Waltham, Mass., reported its third-quarter U.S. net sales of Tymlos (abaloparatide) injection for postmenopausal women with osteoporosis were $27.6 million, compared to approximately $3.5 million for the three months ended Sept. 30. The company recorded a net loss of $49.8 million, or $1.09 per share, compared to a net loss of $57.8 million, or $1.31 per share, for the three months ended Sept. 30.